Growth Metrics

Alnylam Pharmaceuticals (ALNY) Gross Profit (2019 - 2025)

Historic Gross Profit for Alnylam Pharmaceuticals (ALNY) over the last 7 years, with Q4 2025 value amounting to $829.3 million.

  • Alnylam Pharmaceuticals' Gross Profit rose 6906.86% to $829.3 million in Q4 2025 from the same period last year, while for Dec 2025 it was $2.5 billion, marking a year-over-year increase of 2733.91%. This contributed to the annual value of $3.0 billion for FY2025, which is 5639.51% up from last year.
  • Latest data reveals that Alnylam Pharmaceuticals reported Gross Profit of $829.3 million as of Q4 2025, which was up 6906.86% from $1.1 billion recorded in Q3 2025.
  • Alnylam Pharmaceuticals' Gross Profit's 5-year high stood at $1.1 billion during Q3 2025, with a 5-year trough of -$40.2 million in Q1 2025.
  • Over the past 5 years, Alnylam Pharmaceuticals' median Gross Profit value was $283.4 million (recorded in 2022), while the average stood at $380.0 million.
  • Per our database at Business Quant, Alnylam Pharmaceuticals' Gross Profit surged by 19458.29% in 2023 and then plummeted by 10913.83% in 2025.
  • Over the past 5 years, Alnylam Pharmaceuticals' Gross Profit (Quarter) stood at $224.9 million in 2021, then grew by 28.44% to $288.9 million in 2022, then increased by 27.31% to $367.7 million in 2023, then skyrocketed by 33.39% to $490.5 million in 2024, then soared by 69.07% to $829.3 million in 2025.
  • Its Gross Profit stands at $829.3 million for Q4 2025, versus $1.1 billion for Q3 2025 and $631.7 million for Q2 2025.